Literature DB >> 6376646

The role of antibody and complement in the control of viral infections.

N R Cooper, G R Nemerow.   

Abstract

Host defense against viral infection is extremely complex and includes both humoral and cellular immune mechanisms. This contribution examines the mechanisms by which antibody (Ab) and the complement (C) system, major constituents of the humoral immune system, inactivate viruses and block viral maturation in virus-infected cells in vitro. Ab and C may neutralize viruses by envelopment in a coating of protein, by aggregation by lysis, or by facilitating interactions with various effector cells. Ab and C molecules deposited on the surfaces of viruses may physically interfere with the ability of the virus to infect a potentially susceptible cell. This appears to be the most common mechanism by which Ab and C neutralize viruses. In rare instances, Ab and/or C may aggregate viruses; aggregation reduces the net number of infectious particles and thus is manifest as neutralization. C may lyse enveloped viruses, resulting in irreversible viral inactivation. However, this does not appear to be a major mechanism of viral neutralization. Finally, the Fc portions of bound Ab molecules as well as bound C molecules may interact with effector cells with specific receptors for these factors and thereby facilitate viral destruction. In regard to virus-infected cells, the deposition of Ab or C on the cell surface may prevent the maturation or release of viral particles and alter normal cellular functions. Ab and C may also lyse virus-infected cells, abruptly stopping further viral maturation. Such lytic events require only the F(ab')2 portion of the Ab molecule and proceed via activation of the alternative C pathway. Effector cells may also interact with Ab and/or C molecules deposited on virus-infected cells, leading to cytotoxic reactions and/or ingestion depending on the type of effector cell involved. The activated C system has the ability to produce an acute inflammatory response leading to alterations in vessel permeability, edema, changes in smooth-muscle contractility, and the influx of leukocytes. Such inflammatory responses occurring in tissues, including the skin, as a result of C activation not only retard the spread of the infection and facilitate the destruction of the infectious agent, but also in all likelihood damage normal tissues in the vicinity. In addition, C activation in tissues also has the ability to stimulate arachidonic acid metabolism and induce the release of histamine and other mediators as well as pyrogens from appropriate cell types. A number of the systemic symptoms characteristic of viral infections, such as headaches, myalgias, and fever, likely result from such processes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6376646     DOI: 10.1111/1523-1747.ep12281847

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  14 in total

1.  Reciprocal antibody and complement responses of two chicken breeds to vaccine strains of Newcastle disease virus, infectious bursal disease virus and infectious bronchitis virus.

Authors:  R Baelmans; H K Parmentier; P Dorny; F Demey; D Berkvens
Journal:  Vet Res Commun       Date:  2006-07       Impact factor: 2.459

Review 2.  Infections of people with complement deficiencies and patients who have undergone splenectomy.

Authors:  Sanjay Ram; Lisa A Lewis; Peter A Rice
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

3.  Prediction of epitope-based peptides for the utility of vaccine development from fusion and glycoprotein of nipah virus using in silico approach.

Authors:  M Sadman Sakib; Md Rezaul Islam; A K M Mahbub Hasan; A H M Nurun Nabi
Journal:  Adv Bioinformatics       Date:  2014-07-24

Review 4.  Adjuvant Probiotics and the Intestinal Microbiome: Enhancing Vaccines and Immunotherapy Outcomes.

Authors:  Luis Vitetta; Emma Tali Saltzman; Michael Thomsen; Tessa Nikov; Sean Hall
Journal:  Vaccines (Basel)       Date:  2017-12-11

5.  Korean Red Ginseng enhances pneumococcal Δpep27 vaccine efficacy by inhibiting reactive oxygen species production.

Authors:  Si-On Lee; Seungyeop Lee; Se-Jin Kim; Dong-Kwon Rhee
Journal:  J Ginseng Res       Date:  2017-12-09       Impact factor: 6.060

6.  A new method for the detection of neutralizing antibodies against mumps virus.

Authors:  Keita Matsubara; Motoko Fujino; Kaoru Takeuchi; Satoshi Iwata; Tetsuo Nakayama
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

7.  Computer aided epitope design as a peptide vaccine component against Lassa virus.

Authors:  Ar-Rafi Md Faisal; Syed Hassan Imtiaz; Tasnim Zerin; Tania Rahman; Hossain Uddin Shekhar
Journal:  Bioinformation       Date:  2017-12-31

8.  Exploring Lassa Virus Proteome to Design a Multi-epitope Vaccine Through Immunoinformatics and Immune Simulation Analyses.

Authors:  Sifat Bin Sayed; Zulkar Nain; Md Shakil Ahmed Khan; Faruq Abdulla; Rubaia Tasmin; Utpal Kumar Adhikari
Journal:  Int J Pept Res Ther       Date:  2020-01-02       Impact factor: 2.191

9.  Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2.

Authors:  Muhammad Tahir Ul Qamar; Farah Shahid; Sadia Aslam; Usman Ali Ashfaq; Sidra Aslam; Israr Fatima; Muhammad Mazhar Fareed; Ali Zohaib; Ling-Ling Chen
Journal:  Infect Dis Poverty       Date:  2020-09-16       Impact factor: 4.520

10.  The Combination of 2'-Fucosyllactose with Short-Chain Galacto-Oligosaccharides and Long-Chain Fructo-Oligosaccharides that Enhance Influenza Vaccine Responses Is Associated with Mucosal Immune Regulation in Mice.

Authors:  Ling Xiao; Phillip A Engen; Thea Leusink-Muis; Ingrid van Ark; Bernd Stahl; Saskia A Overbeek; Johan Garssen; Ankur Naqib; Stefan J Green; Ali Keshavarzian; Gert Folkerts; Belinda Van't Land
Journal:  J Nutr       Date:  2019-05-01       Impact factor: 4.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.